## SAES

December 2021, Consolidated Results



## Financial Highlights - 2021 - YTD

> EXCEEDED ALL PRE-PANDEMIC FIGURES
> QUATERLY REVENUES SHOWING PROGRESSIVE GROWTH
$>$ STRONG INCREASE IN MARGINS AND IN THE NET INCOME, TRIPLED COMPARED TO 2020, DESPITE UNFAVORABLE CHANGES AND SOME NON-RECURRING COSTS

PROPOSED A DIVIDEND OF $€ 0.47$ (BOTH PER ORDINARY SHARE AND SAVINGS SHARE)


## Financial Highlights - 2021 - QTD

| P\&L figures | 4Q 2021 | 4Q 2020 | Total difference | $\begin{gathered} \text { Difference } \\ \% \end{gathered}$ | 3Q 2021 | Total difference | $\begin{gathered} \text { Difference } \\ \% \\ \hline \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| CONSOLIDATED REVENUES | 53.1 | 40.6 | 12.5 | 30.7\% | 51.3 | 1.8 | 3.5\% |
| TOTAL REVENUES OF THE GROUP | 54.6 | 43.1 | 11.6 | 26.8\% | 53.9 | 0.8 | 1.5\% |
| CONSOLIDATED GROSS PROFIT | 23.3 | 15.9 | 7.4 | 46.5\% | 22.6 | 0.6 | 2.9\% |
| \% on sales | 43.9\% | 39.1\% |  |  | 44.2\% |  |  |
| CONSOLIDATED OPERATING INCOME | 5.6 | 2.3 | 3.4 | 149.3\% | 9.5 | (3.8) | -40.5\% |
| $\%$ on sales | 10.6\% | 5.6\% |  |  | 18.5\% |  |  |
| CONSOLIDATED EBITDA | 10.4 | 5.0 | 5.4 | 107.6\% | 12.3 | (1.9) | -15.4\% |
| \% on sales | 19.6\% | 12.3\% |  |  | 24.0\% |  |  |
| CONSOLIDATED INCOME (LOSS) BEFORE TAXES | 4.5 | 1.9 | 2.6 | 139.5\% | 9.4 | (4.9) | -52.2\% |
| $\%$ on sales | 8.4\% | 4.6\% |  |  | 18.2\% |  |  |
| CONSOLIDATED NET INCOME (LOSS) | 2.6 | 1.7 | 0.9 | 54.3\% | 6.3 | (3.8) | -59.7\% |
| \% on sales | 4.8\% | 4.1\% |  |  | 12.4\% |  |  |

## saes

## Metallurgy Division Sales

Metallurgy Division
32.8\%

|  | 2021 | 2020 | Total <br> difference <br> $\%$ | Consolid. area effect | Organic change \% | Exchange rate effect \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Security \& Defense | 18.2 | 17.3 | 5.0\% | 0.0\% | 7.5\% | -2.5\% |
| Electronic Devices | 13.2 | 17.0 | -22.5\% | 0.0\% | -21.0\% | -1.5\% |
| Healthcare Diagnostics | 5.2 | 4.5 | 16.9\% | 0.0\% | 18.8\% | -1.9\% |
| Lamps | 3.0 | 3.2 | -7.7\% | 0.0\% | -6.3\% | -1.4\% |
| Thermal Insulated Devices | 3.5 | 3.0 | 16.4\% | 0.0\% | 20.9\% | 4.5\% |
| Sintered Components for Electronic Devices \& Lasers | 8.6 | 7.2 | 19.7\% | 0.0\% | 23.9\% | 4.2\% |
| SMA Industrial | 10.7 | 10.9 | -1.7\% | 0.0\% | -0.3\% | -1.4\% |
| Metallurgy Division | 62.3 | 63.0 | -1.2\% | 0.0\% | 1.0\% | -2.2\% |


|  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Security \& Defense | 4.6 | 4.9 | 3.4 | 4.4 | 4.3 | 4.7 | 5.0 | 4.1 |
| Electronic Devices | 4.2 | 3.5 | 5.2 | 4.1 | 3.4 | 2.8 | 3.4 | 3.6 |
| Healthcare Diagnostics | 1.7 | 1.1 | 0.9 | 0.8 | 1.2 | 1.3 | 1.2 | 1.5 |
| Lamps | 1.1 | 0.9 | 0.6 | 0.7 | 0.8 | 0.7 | 0.7 | 0.7 |
| Thermal Insulated Devices | 1.0 | 0.7 | 0.6 | 0.8 | 0.9 | 0.7 | 0.9 | 1.0 |
| Sintered Components for Electronic Devices \& Lasers | 2.1 | 1.7 | 1.8 | 1.6 | 1.9 | 2.1 | 2.2 | 2.3 |
| SMA Industrial | 3.9 | 2.3 | 2.2 | 2.4 | 2.8 | 2.4 | 3.0 | 2.4 |
| Metallurgy Division | $\mathbf{1 8 . 4}$ | $\mathbf{1 5 . 1}$ | $\mathbf{1 4 . 6}$ | $\mathbf{1 4 . 9}$ | $\mathbf{1 5 . 4}$ | $\mathbf{1 4 . 8}$ | $\mathbf{1 6 . 5}$ | $\mathbf{1 5 . 6}$ |

$\checkmark$ Organic growth driven by the Sintered Components for Electronic Devices \& Lasers Business (heat sinks for SSL and electron emitters for med), the Security \& Defense Business (getters for night vision and hydrogen absorbers for TLC applications) and the Healthcare Diagnostics Business (porous getters for X-ray tubes)
$\checkmark$ Electronic Devices Business penalized by the slowdown in the thermal sensors market, after the peak of the $1^{\text {st }}$ phase of the pandemic
$\checkmark$ Lamps Business: structural decrease, due to the continued decline in the market for linear fluorescent lamps
$\checkmark$ Thermal Insulated Devices Business: stability in the getters for vacuum bottles but increased demand of getters for CSP (solar) and for VIP used for the transport of vaccines

SEES
$\checkmark$ SMA Industrial Business: growth in the luxury goods and medical dispensers offset by lower sales in consumer electronics applications in the TLC sector, penalized by the US-China tensions

## Vacuum Technology Division Sales

Vacuum Technology Division
9.9\%

|  | 2021 | $\mathbf{2 0 2 0}$ | Total <br> difference <br> $\%$ | Consolid. <br> area <br> effect | Organic <br> change <br> $\%$ | Exchange <br> rate effect <br> $\%$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Solutions for Vacuum Systems | 18.8 | 12.5 | $51.0 \%$ | $15.2 \%$ | $38.7 \%$ | $-2.9 \%$ |
| Vacuum Technology Division | $\mathbf{1 8 . 8}$ | $\mathbf{1 2 . 5}$ | $\mathbf{5 1 . 0} \%$ | $\mathbf{1 5 . 2 \%}$ | $\mathbf{3 8 . 7 \%}$ | $\mathbf{- 2 . 9 \%}$ |


|  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  |  |  |  | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |  |
| Solutions for Vacuum Systems | 2.4 | 2.9 | 3.0 | 4.1 | 3.2 | 5.5 | 3.3 | 6.9 |
| Vacuum Technology Division | 2.4 | 2.9 | 3.0 | 4.1 | $\mathbf{3 . 2}$ | $\mathbf{5 . 5}$ | $\mathbf{3 . 3}$ | $\mathbf{6 . 9}$ |

$\checkmark$ Higher sales of vacuum pumps in all sectors, especially in the particle accelerators
$\checkmark$ Growing success of the innovative products developed by SAES in the last few years
$\checkmark$ Consolidation of the revenues of Strumenti Scientifici Cinel S.r.l. acquired in July 2021

## Medical Division Sales

|  | $\mathbf{2 0 2 1}$ | $\mathbf{2 0 2 0}$ | Total <br> difference <br> $\%$ | Consolid. <br> area <br> effect | Organic <br> change <br> $\%$ | Exchange <br> rate effect <br> $\%$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Nitinol for Medical Devices | 86.4 | 73.6 | $17.5 \%$ | $0.0 \%$ | $21.6 \%$ | $-4.1 \%$ |
| Medical Division | $\mathbf{8 6 . 4}$ | $\mathbf{7 3 . 6}$ | $\mathbf{1 7 . 5 \%}$ | $\mathbf{0 . 0 \%}$ | $\mathbf{2 1 . 6 \%}$ | $-\mathbf{4 . 1 \%}$ |


|  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Nitinol for Medical Devices | 21.6 | 18.6 | 16.4 | 17.0 | 18.0 | 20.5 | 23.9 | 24.0 |
| Medical Division | 21.6 | 18.6 | 16.4 | 17.0 | 18.0 | 20.5 | 23.9 | 24.0 |

$\checkmark$ Two-digit organic growth confirming the recovery of the market from 2Q 2021, after the slowdown in 2020 due to Covid-19 impact on elective surgeries

## saes

|  | $\mathbf{2 0 2 1}$ | $\mathbf{2 0 2 0}$ | Total <br> difference <br> $\%$ | Consolid. <br> area <br> effect | Organic <br> change <br> $\%$ | Exchange <br> rate effect <br> $\%$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Functional Dispensable Products | 16.8 | 12.2 | $37.6 \%$ | $0.0 \%$ | $38.1 \%$ | $-0.5 \%$ |
| Specialty Chemicals Division | $\mathbf{1 6 . 8}$ | $\mathbf{1 2 . 2}$ | $\mathbf{3 7 . 6 \%}$ | $\mathbf{0 . 0 \%}$ | $\mathbf{3 8 . 1 \%}$ | $\mathbf{- 0 . 5 \%}$ |


|  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Functional Dispensable Products | 4.3 | 0.7 | 3.4 | 3.8 | 2.7 | 2.9 | 6.5 | 4.6 |
| Specialty Chemicals Division | 4.3 | 0.7 | 3.4 | 3.8 | 2.7 | 2.9 | 6.5 | 4.6 |

[^0]
## Advanced Packaging Division Sales



|  | 2021 | 2020 | $\begin{array}{\|c\|} \hline \text { Total } \\ \text { difference } \\ \% \\ \hline \end{array}$ | Consolid. <br> area effect | Organic change \% | Exchange rate effect \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Advanced Coatings | 5.9 | 7.4 | -21.0\% | 0.0\% | -21.0\% | 0.0\% |
| Advanced Packaging Division | 5.9 | 7.4 | -21.0\% | 0.0\% | -21.0\% | 0.0\% |


|  | 1Q 2020 | 2 Q 2020 | 3 Q 2020 | 4 Q 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Advanced Coatings | 2.6 | 2.4 | 1.5 | 0.9 | 1.7 | 1.2 | 1.1 | 1.9 |
| Advanced Packaging Division | 2.6 | 2.4 | 1.5 | 0.9 | 1.7 | 1.2 | 1.1 | 1.9 |

$\checkmark \quad$ FY sales decrease exclusively due to the phase-out of metalized products, completed in the second half of 2020
$\checkmark$ Increased sales of lacquered products: excellent performance in the last few months due to both the expansion of the customer portfolio and the conjunctural unavailability of some polymers favoring a greater penetration of SAES products

Consolidated Net Sales - 2021 quarterly trend

|  | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :---: | :---: | :---: | :---: | :---: |
| Security \& Defense | 4.3 | 4.7 | 5.0 | 4.1 |
| Electronic Devices | 3.4 | 2.8 | 3.4 | 3.6 |
| Healthcare Diagnostics | 1.2 | 1.3 | 1.2 | 1.5 |
| Lamps | 0.8 | 0.7 | 0.7 | 0.7 |
| Thermal Insulated Devices | 0.9 | 0.7 | 0.9 | 1.0 |
| Sintered Components for Electronic Devices \& Lasers | 1.9 | 2.1 | 2.2 | 2.3 |
| SMA Industrial | 2.8 | 2.4 | 3.0 | 2.4 |
| Metallurgy Division | 15.4 | 14.8 | 16.5 | 15.6 |
| Solutions for Vacuum Systems | 3.2 | 5.5 | 3.3 | 6.9 |
| Vacuum Technology Division | 3.2 | 5.5 | 3.3 | 6.9 |
| Nitinol for Medical Devices | 18.0 | 20.5 | 23.9 | 24.0 |
| Medical Division | 18.0 | 20.5 | 23.9 | 24.0 |
| Functional Dispensable Products | 2.7 | 2.9 | 6.5 | 4.6 |
| Specialty Chemicals Division | 2.7 | 2.9 | 6.5 | 4.6 |
| Advanced Coatings | 1.7 | 1.2 | 1.1 | 1.9 |
| Advanced Packaging Division | 1.7 | 1.2 | 1.1 | 1.9 |
| Consolidated net sales | 41.0 | 44.8 | 51.3 | 53.1 |

$\checkmark$ Gradual growth in all quarters of 2021, driven by the Medical Division, that exceeded pre-Covid levels

Consolidated Net Sales - 4Q 2021 vs. 3Q 2021

Thousands of euro (except \%)

| Business | 4Q 2021 | 3Q 2021 | Total difference | Organic change | Exchange rate effect |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Security \& Defense | 4.1 | 5.0 | -17.9\% | -19.6\% | 1.7\% |
| Electronic Devices | 3.6 | 3.4 | 6.2\% | 4.2\% | 2.0\% |
| Healthcare Diagnostic | 1.5 | 1.2 | 17.4\% | 15.7\% | 1.7\% |
| Lamps | 0.7 | 0.7 | -9.1\% | -10.5\% | 1.4\% |
| Thermal Insulated Devices | 1.0 | 0.9 | 17.1\% | 15.5\% | 1.6\% |
| Sintered Components for Electronic Devices \& Lasers | 2.3 | 2.2 | 4.2\% | 1.1\% | 3.1\% |
| SMA Industrial | 2.4 | 3.0 | -18.1\% | -18.9\% | 0.8\% |
| Metallurgy Division | 15.6 | 16.5 | -5.1\% | -6.9\% | 1.8\% |
| Solutions for Vacuum Systems | 6.9 | 3.3 | 109.6\% | 107.1\% | 2.5\% |
| Vacuum Technology Division | 6.9 | 3.3 | 109.6\% | 107.1\% | 2.5\% |
| Nitinol for Medical Devices | 24.0 | 23.9 | 0.2\% | -2.8\% | 3.0\% |
| Medical Division | 24.0 | 23.9 | 0.2\% | -2.8\% | 3.0\% |
| Functional Dispensable Products | 4.6 | 6.5 | -28.8\% | -28.9\% | 0.1\% |
| Specialty Chemicals Division | 4.6 | 6.5 | -28.8\% | -28.9\% | 0.1\% |
| Advanced Coatings | 1.9 | 1.1 | 81.5\% | 81.5\% | 0.0\% |
| Advanced Packaging Divison | 1.9 | 1.1 | 81.5\% | 81.5\% | 0.0\% |
| Total net sales | 53.1 | 51.3 | 3.5\% | 1.4\% | 2.1\% |

$\checkmark$ Metallurgy Division: organic decrease particularly in the security and defense sector (slowdown exclusively due to the dynamics of inventories, after three quarters of progressive growth) and in he industrial SMAs (slowdown in the automotive sector due to the chip crunch and lower sales in the TLC sector)
$\checkmark$ Vacuum Technology Division: some important projects in the field of particle accelerators and increased sales of vacuum pumps to universities
$\checkmark$ Medical Division substantially stable
$\checkmark$ Specialty Chemicals Division: decrease after high sales in 3Q due to postponement of some deliveries to 2022
$\checkmark$ Advanced Packaging Division: strong growth thanks to new customers in the portfolio and the favorable economic conditions, which allowed a larger penetration of the innovative SAES offer

## Total revenues of the Group

(achieved by incorporating the JVs with the proportional method instead of the equity method)


[^1]saes

## Consolidated Sales by Geographic Area - FY 2021

## Actual 2021 - Total 190,198



Actual 2020 - Total 168,703


## saes

## Consolidated Sales by Invoicing Currency - FY 2021

Actual 2021 - Total 190,198


Actual 2020 - Total 168,703


## saes

## Consolidated Costs* by Currency - FY 2021



Actual 2020 - Total 151,833


## saes

## Metallurgy Division Margins

|  | 2021 | 2020 | Total difference |  |  |  |  |  |  | All figures in $M €$, unless otherwise stated |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 62.3 | 63.0 | (0.7) |  |  |  |  |  |  |  |  |  |  |
| GROSS PROFIT | 32.2 | 31.3 | 0.9 |  |  |  |  |  |  |  |  |  |  |
| Gross Margin | 51.7\% | 49.6\% |  |  |  |  |  |  |  |  |  |  |  |
| OPERATING INCOME | 21.8 | 20.2 | 1.7 |  |  |  |  |  |  |  |  |  |  |
| Operating Margin | 35.0\% | 32.0\% |  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | FY 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 | FY 2021 |
|  |  | NET S | ALES | 18.4 | 15.1 | 14.6 | 14.9 | 63.0 | 15.4 | 14.8 | 16.5 | 15.6 | 62.3 |
|  |  | GROS | S PROFIT | 9.6 | 7.5 | 6.9 | 7.3 | 31.3 | 8.0 | 7.7 | 8.9 | 7.6 | 32.2 |
|  |  | Gross | Margin | 52.0\% | 49.6\% | 47.2\% | 49.1\% | 49.6\% | 52.0\% | 52.4\% | 53.9\% | 48.4\% | 51.7\% |
|  |  | OPER | ATING INCOME | 6.6 | 4.6 | 4.3 | 4.7 | 20.2 | 5.2 | 5.4 | 6.5 | 4.7 | 21.8 |
|  |  | Operating | ing Margin | 36.0\% | 30.3\% | 29.3\% | 31.3\% | 32.0\% | 33.8\% | 36.6\% | 39.2\% | 30.3\% | 35.0\% |

$\checkmark$ Increase both in gross profit and gross margin in almost all sectors, mainly driven by Healthcare Diagnostics, Lamps, Sintered Components for Electronic Devices \& Lasers and SMA Industrial
$\checkmark$ Security \& Defense margin was stable
$\checkmark$ Decrease in Electronic Devices margin (lower sales and lower economies of scale) and in Thermal Insulated Devices margin (different offer balance)
SEES
$\checkmark$ Strong increase in operating income and operating margin mainly thanks to the increase in gross profit and to the decrease in operating expenses

## Vacuum Technology Division Margins

|  | 2021 | 2020 | Total <br> difference |
| :--- | ---: | ---: | ---: |
| NET SALES | 18.8 | 12.5 | 6.4 |
| GROSS PROFIT | 10.1 | 7.5 | $\mathbf{2 . 6}$ |
| Gross Margin | $53.5 \%$ | $60.1 \%$ |  |
| OPERATING INCOME | 5.1 | 3.7 | $\mathbf{1 . 4}$ |
| Operating Margin | $27.2 \%$ | $29.7 \%$ |  |
|  |  |  |  |


|  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | FY 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 | FY 2021 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| NET SALES | 2.4 | 2.9 | 3.0 | 4.1 | 12.5 | 3.2 | 5.5 | 3.3 | 6.9 | 18.8 |
| GROSS PROFIT | 1.4 | 1.9 | 1.9 | 2.3 | 7.497 | 1.6 | 3.1 | 1.9 | 3.5 | 10.1 |
| Gross Margin | $58.7 \%$ | $63.5 \%$ | $62.0 \%$ | $57.1 \%$ | $60.1 \%$ | $49.1 \%$ | $56.1 \%$ | $58.7 \%$ | $50.9 \%$ | $53.5 \%$ |
| OPERATING INCOME |  |  |  |  |  |  |  |  |  |  |
| Operating Margin | 0.5 | 0.9 | 1.0 | 1.3 | 3.7 | $\mathbf{0 . 6}$ | 1.8 | 0.9 | 1.8 | 5.1 |

$\checkmark$ Strong increase in gross profit exclusively attributable to higher sales
$\checkmark$ Decrease in gross margin only attributable to the consolidation of the newly acquired Strumenti Scientifici Cinel S.r.l., as well as to a different mix of supply contribution and higher raw material costs as well

## saes

$\checkmark$ Operating income almost doubled, entirely due to the increase in sales and gross profit

## Medical Division Margins

|  | 2021 | 2020 | Total <br> difference |
| :--- | ---: | ---: | ---: |
| NET SALES | 86.4 | 73.6 | 12.8 |
| GROSS PROFIT | 34.3 | 27.9 | 6.3 |
| Gross Margin | $39.7 \%$ | $38.0 \%$ |  |
| OPERATING INCOME | 25.6 | 19.8 | 5.8 |
| Operating Margin | $29.7 \%$ | $27.0 \%$ |  |


|  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | FY 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 | FY 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 21.6 | 18.6 | 16.4 | 17.0 | 73.6 | 18.0 | 20.5 | 23.9 | 24.0 | 86.4 |
| GROSS PROFIT | 8.0 | 7.8 | 6.1 | 6.0 | 27.9 | 5.7 | 7.9 | 9.9 | 10.7 | 34.3 |
| Gross Margin | 37.2\% | 42.1\% | 37.1\% | 35.3\% | 38.0\% | 32.0\% | 38.3\% | 41.5\% | 44.8\% | 39.7\% |
| OPERATING INCOME | 5.8 | 5.8 | 4.2 | 4.1 | 19.8 | 3.6 | 5.8 | 7.7 | 8.5 | 25.6 |
| Operating Margin | 26.8\% | 31.1\% | 25.4\% | 24.1\% | 27.0\% | 20.1\% | 28.2\% | 32.2\% | 35.6\% | 29.7\% |

$\checkmark$ Increase both in gross profit and gross margin thanks to the overcoming of the pandemic crisis
$\checkmark$ Strong acceleration in the last part of the year, despite the persistence of extra costs due to the launch of the new tube production line in Bethel

## saes

$\checkmark$ Strong increase also in operating income, solely attributable to higher sales, after the overcoming of the Covid-19 crisis
$\checkmark$ Physiological increase in operating expenses (higher personnel cost, bonuses and consultancy, proportional to higher sales)

## Specialty Chemicals Division Margins

|  | 2021 | 2020 | Total <br> difference |
| :--- | ---: | ---: | ---: |
| NET SALES | 16.8 | 12.2 | 4.6 |
| GROSS PROFIT | 4.9 | 3.3 | 1.7 |
| Gross Margin | $29.5 \%$ | $27.0 \%$ |  |
| OPERATING INCOME | 2.6 | 1.6 | 1.0 |
| Operating Margin | $15.2 \%$ | $12.8 \%$ |  |
|  |  |  |  |


|  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | FY 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 | FY 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 4.3 | 0.7 | 3.4 | 3.8 | 12.2 | 2.7 | 2.9 | 6.5 | 4.6 | 16.8 |
| GROSS PROFIT | 1.1 | 0.3 | 1.0 | 0.8 | 3.3 | 0.7 | 0.8 | 2.2 | 1.2 | 4.9 |
| Gross Margin | 25.1\% | 43.0\% | 30.5\% | 22.6\% | 27.0\% | 27.1\% | 29.4\% | 33.5\% | 25.2\% | 29.5\% |
| OPERATING INCOME | 0.6 | 0.0 | 0.6 | 0.4 | 1.6 | 0.3 | 0.3 | 1.6 | 0.5 | 2.6 |
| Operating Margin | 12.9\% | 0.4\% | 17.4\% | 11.0\% | 12.8\% | 9.4\% | 9.0\% | 24.0\% | 10.3\% | 15.2\% |

$\checkmark$ Two-digit increase (+50.3\%) in gross profit and increase in gross margin both driven by the increase in sales of advanced solutions for the consumer electronics market and by the resulting economies of scale
$\checkmark$ Operating income significantly up (+63.4\%) primarily thanks to increase in gross profit

Advanced Packaging Division Margins

|  | 2021 | 2020 | Total difference |  |  |  |  |  | All figures in $M €$, unless otherwise stated |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 5.9 | 7.4 | (1.6) |  |  |  |  |  |  |  |  |  |  |
| GROSS PROFIT | 0.2 | 0.5 | -0.4 |  |  |  |  |  |  |  |  |  |  |
| Gross Margin | 2.6\% | 7.3\% |  |  |  |  |  |  |  |  |  |  |  |
| OPERATING INCOME | (6.1) | (2.5) | -3.6 |  |  |  |  |  |  |  |  |  |  |
| Operating Margin | -103.5\% | -33.9\% |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | FY 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 | FY 2021 |
|  |  |  | ET SALES | 2.6 | 2.4 | 1.5 | 0.9 | 7.4 | 1.7 | 1.2 | 1.1 | 1.9 | 5.9 |
|  |  |  | ROSS PROFIT | 0.2 | 0.4 | 0.1 | (0.1) | 0.5 | 0.1 | 0.0 | (0.3) | 0.3 | 0.2 |
|  |  |  | ross Margin | 9.6\% | 14.7\% | 5.5\% | -16.7\% | 7.3\% | 6.4\% | 0.8\% | -26.0\% | 16.1\% | 2.6\% |
|  |  |  | PERATING INCOME | (0.6) | (0.6) | (0.6) | (0.8) | (2.5) | (0.7) | (0.9) | (1.1) | (3.3) | (6.1) |
|  |  |  | perating Margin | -22.1\% | -22.6\% | -39.2\% | -90.2\% | -33.9\% | -42.4\% | -75.0\% | -108.7\% | -173.2\% | -103.5\% |

$\checkmark$ Slightly positive gross profit but decreasing compared to 2020, due to lower economies of scale and to the initial operating phase of the second lacquering line
$\checkmark$ Increased operating loss: net of non-recurring, the operating loss would have been equal to - $€ 3.5$ million (worsening due to both lower gross profit and higher R\&D expenses for the development of new functional lacquers for active packaging)

## saes

[^2]
## Not Allocated Costs

|  | 2021 | $\mathbf{2 0 2 0}$ | Total <br> difference |
| :--- | ---: | ---: | ---: |
| NET SALES | $\mathbf{0 . 0}$ | $\mathbf{0 . 0}$ | $\mathbf{0 . 0}$ |
| GROSS PROFIT | $\mathbf{( 0 . 3 )}$ | $\mathbf{- 0 . 4}$ | $\mathbf{0 . 1}$ |
| Gross Margin | n.a. | n.a. |  |
| Total operating expenses | $(26.2)$ | $(25.3)$ | $(0.9)$ |
| Other income (expenses), net | 0.2 | $(0.7)$ | 0.9 |
| OPERATING INCOME | $\mathbf{( 2 6 . 4 )}$ | $\mathbf{( 2 6 . 5 )}$ | $\mathbf{0 . 1}$ |
| Operating Margin | n.a. | n.a. |  |
|  |  |  |  |


$\checkmark$ Unallocated costs of sales related to the project to renovate and make safe some production departments at the Lainate site
$\checkmark$ Operating loss substantially unchanged
$\checkmark$ Reduction in personnel costs and consultancy costs (in the G\&A expenses) more than offset by an increase in the same type of costs in the R\&D and SE expenses

## SEES

Consolidated Income Statement - 2021
All figures in $M €$, unless otherwise stated

|  | 2021 | 2020 | Total difference | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 | FY 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 190.2 | 168.7 | 21.5 | 41.0 | 44.8 | 51.3 | 53.1 | 190.2 |
| GROSS PROFIT | 81.3 | 70.1 | 11.2 | 15.9 | 19.5 | 22.6 | 23.3 | 81.3 |
| Gross Margin | 42.8\% | 41.6\% |  | 38.8\% | 43.4\% | 44.2\% | 43.9\% | 42.8\% |
| R\&D expenses | (11.7) | (10.4) | (1.3) | (2.8) | (2.8) | (2.9) | (3.1) | (11.7) |
| Selling expenses | (13.0) | (11.1) | (1.9) | (2.9) | (3.2) | (3.1) | (3.9) | (13.0) |
| G\&A expenses | (33.1) | (31.7) | (1.4) | (7.9) | (8.1) | (7.1) | (10.0) | (33.1) |
| Total operating expenses | (57.8) | (53.2) | (4.6) | (13.6) | (14.1) | (13.1) | (17.0) | (57.8) |
| Other income (expenses), net | (0.8) | (0.6) | (0.2) | (0.1) | (0.0) | (0.1) | (0.6) | (0.8) |
| OPERATING INCOME | 22.6 | 16.3 | 6.4 | 2.2 | 5.3 | 9.5 | 5.6 | 22.6 |
| Operating Margin | 11.9\% | 9.6\% |  | 5.5\% | 11.8\% | 18.5\% | 10.6\% | 11.9\% |
| Interest and other financial income (expenses), net | 2.0 | (1.2) | 3.3 | 0.5 | 0.8 | (0.1) | 0.8 | 2.0 |
| Write down of financial receivables and other financial assets | (2.1) | (3.0) | 0.8 | (0.2) | (0.0) | (0.1) | (1.9) | (2.1) |
| Income (loss) from equity method evalueted companies | 0.2 | (1.7) | 1.9 | 0.0 | 0.1 | 0.1 | 0.0 | 0.2 |
| Write dow n of investments accounted for using the equity method | 0.0 | (0.6) | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Foreign exchange gains (losses), net | (0.2) | (0.5) | 0.2 | (0.1) | 0.0 | (0.1) | (0.1) | (0.2) |
| INCOME BEFORE TAXES | 22.5 | 9.3 | 11.8 | 2.5 | 6.2 | 9.4 | 4.5 | 22.5 |
| Income taxes | (9.4) | (4.5) | (4.9) | (1.1) | (3.4) | (3.0) | (1.9) | (9.4) |
| NET INCOME from continued operations | 13.1 | 4.8 | 6.9 | 1.4 | 2.8 | 6.3 | 2.6 | 13.1 |
| Net Margin | 6.9\% | 2.8\% |  | 3.4\% | 6.3\% | 12.4\% | 4.8\% | 6.9\% |
| Net income from discontinued operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| NET INCOME before minority interests | 13.1 | 4.8 | 6.9 | 1.4 | 2.8 | 6.3 | 2.6 | 13.1 |
| Net Margin | 6.9\% | 2.8\% |  | 3.4\% | 6.3\% | 12.4\% | 4.8\% | 6.9\% |
| Minority interests | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| GROUP NET INCOME | 13.1 | 4.8 | 6.9 | 1.4 | 2.8 | 6.3 | 2.6 | 13.1 |
| Net Margin | 6.9\% | 2.8\% |  | 3.4\% | 6.3\% | 12.4\% | 4.8\% | 6.9\% |

## sees

## One-offs - FY 2021

|  | 2021 | $2021$ <br> one-offs | $\begin{gathered} 2021 \\ \text { net of one-offs } \end{gathered}$ |
| :---: | :---: | :---: | :---: |
| NET SALES | 190.2 | 0.0 | 190.2 |
| GROSS PROFIT | 81.3 | 0.0 | 81.3 |
| Gross Margin | 42.8\% | n.s. | 42.8\% |
| R\&D expenses | (11.7) | 0.0 | (11.7) |
| Selling expenses | (13.0) | 0.0 | (13.0) |
| G\&A expenses | (33.1) | (1.5) (*) | (31.6) |
| Total operating expenses | (57.8) | (1.5) | (56.3) |
| Other income (expenses), net | (0.8) | (0.7) (**) | (0.2) |
| OPERATING INCOME | 22.6 | (2.2) | 25 |
| Operating Margin | 11.9\% | n.s. | 13.0\% |
| CONSOLIDATED EBITDA | 35.9 | (2.2) | 38.1 |
| \% on sales | 18.9\% |  | 20.0\% |

(*) Impairment test write-down on the Advanced Packaging CGU (-€1.5m)
${ }^{* *}$ ) Cancellation of the advanced payment for a potential minority equity investment afterwards suspended (-€1.1m) \& Tax credit on R\&D expenses ( $+€ 0.4 \mathrm{~m}$ )

## saes

## One-offs - FY 2020

|  | 2020 | $\begin{gathered} 2020 \\ \text { one-offs } \end{gathered}$ | $\begin{gathered} 2020 \\ \text { net of one-offs } \end{gathered}$ |
| :---: | :---: | :---: | :---: |
| Net SALES | 168.7 | 0.0 | 168.7 |
| GROSS PROFIT | 70.1 | 0.0 | 70.1 |
| Gross Margin | 41.6\% | n.s. | 41.6\% |
| R\&D expenses | (10.4) | 0.0 | (10.4) |
| Selling expenses | (11.1) | 0.0 | (11.1) |
| G\&A expenses | (31.7) | 0.0 | (31.7) |
| Total operating expenses | (53.2) | 0.0 | (53.2) |
| Other income (expenses), net | (0.6) | (0.4) (*) | (0.2) |
| OPERATING INCOME | 16.3 | (0.4) | 17 |
| Operating Margin | 9.6\% | n.s. | 9.9\% |
| CONSOLIDATED EBITDA | 27.2 | (0.4) | 27.6 |
| \% on sales | 16.1\% |  | 16.4\% |

(*) Donations for Covid-19 (-€0.7m) \& Tax credit on R\&D expenses ( $+€ 0.3 m$ ) \& Tax credit on sanification costs (+€32 thousands)

## saes



## saes

Covid-19 One-offs - 2021

|  | 2021 |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Covid-19 one-offs | Direct <br> Labor | Manufacturing Overhead | R\&D expenses | SE expenses | G\&A expenses | Total |
| Personnel cost <br> Maintenance and repairs <br> Material and office material <br> Transports <br> Consultant fees <br> General services (canteen, cleaning, vigilance, etc.) <br> Training <br> Other costs | (34) | (15) | (6) | (3) | $\begin{array}{r} 23 \\ 142 \\ 9 \\ 0 \\ 2 \\ 169 \\ 0 \\ 2 \end{array}$ | $\begin{array}{r}(35) \\ 142 \\ 9 \\ 0 \\ 2 \\ 169 \\ 0 \\ 2 \\ \hline\end{array}$ |
| Total COGS and OPEX | (34) | (15) | (6) | (3) | 347 | 289 |

## (*) The amount is composed by:

- saving for USA governmental misures to support companies and families, for -62 thousands of euro;
- additional personnel costs, for 27 thousands of euro.


## saes

Covid-19 One-offs - 2020

|  | 2020 |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Covid-19 one-offs | Direct <br> Labor | Manufacturing Overhead | R\&D expenses | SE expenses | G\&A expenses | Total |
| Personnel cost | (156) | (76) | (54) | (13) | 38 | (261) |
| Maintenance and repairs |  |  |  |  | 164 | 164 |
| Depreciation |  |  |  |  | 2 | 2 |
| Material and office material |  |  |  |  | 132 | 132 |
| Transports |  |  |  |  | 4 | 4 |
| Consultant fees |  |  |  |  | 135 | 135 |
| General services (canteen, cleaning, vigilance, etc.) |  |  |  |  | 147 | 147 |
| Training |  |  |  |  | 3 | 3 |
| Other costs |  |  |  |  | 2 | 2 |
| Total COGS and OPEX | (156) | (76) | (54) | (13) | 627 | 328 |

(*) The amount is composed by:

- CIGO savings in Lainate plant, for -55 thousands of euro;
- saving for USA governmental misures to support companies and families, for -260 thousands of euro;
- additional personnel costs, for 54 thousands of euro.

| Covid-19 one-offs | 2020 |
| :--- | ---: |
| Other income | 32 |
| Other expenses | $(691)$ |
| Total other income (expenses) | $\mathbf{( 6 5 9 )}$ |

## saes

## Actuator Solutions - Income Statement

All figures in $M €$, unless otherwise stated

|  | 2021 | 2020 | Total difference | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 12.4 | 14.2 | (1.8) | 4.5 | 3.4 | 2.9 | 3.4 | 4.3 | 2.8 | 3.8 | 1.4 |
| Cost of goods sold | (9.1) | (10.7) | 1.6 | (3.6) | (2.1) | (2.3) | (2.7) | (2.9) | (2.1) | (3.0) | (1.1) |
| GROSS PROFIT | 3.2 | 3.5 | (0.3) | 0.9 | 1.3 | 0.7 | 0.7 | 1.4 | 0.7 | 0.8 | 0.3 |
| Gross Margin | 26.3\% | 24.8\% |  | 19.2\% | 38.0\% | 22.7\% | 20.5\% | 33.4\% | 23.9\% | 20.6\% | 24.4\% |
| Operating expenses | (2.5) | (2.5) | 0.1 | (0.6) | (0.7) | (0.7) | (0.6) | (0.6) | (0.7) | (0.6) | (0.6) |
| Other income (expenses), net | 0.2 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | (0.0) | 0.0 | 0.0 | 0.0 | 0.1 |
| OPERATING INCOME | 1.0 | 1.1 | (0.2) | 0.2 | 0.8 | (0.0) | 0.1 | 0.9 | 0.0 | 0.2 | (0.1) |
| Operating Margin | 7.8\% | 8.0\% |  | 5.5\% | 23.0\% | -0.1\% | 3.2\% | 19.7\% | 1.3\% | 4.1\% | -5.8\% |
| Interest and other financial income (expenses), net | 0.3 | (0.6) | 0.9 | (0.2) | (0.1) | (0.1) | (0.2) | (0.1) | 0.5 | (0.1) | (0.1) |
| Foreign exchange gains (losses), net | (0.0) | (0.2) | 0.1 | (0.0) | (0.0) | (0.1) | 0.0 | (0.0) | 0.0 | (0.0) | (0.0) |
| INCOME BEFORE TAXES | 1.2 | 0.4 | 0.8 | 0.1 | 0.6 | (0.3) | (0.0) | 0.7 | 0.6 | 0.1 | (0.2) |
| Income Taxes | (0.0) | (0.0) | (0.0) | 0.0 | 0.0 | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | 0.0 |
| NET INCOME(LOSS) | 1.2 | 0.4 | 0.8 | 0.1 | 0.6 | (0.3) | (0.0) | 0.7 | 0.6 | 0.1 | (0.1) |

$\checkmark$ Net revenues slightly down compared to 2020, but the two years are not comparable since Actuator Solutions sold three production line of actuators for the seat comfort business to its partner Alfmeier, renouncing sales, but receiving a commission equal to the margin that it would have realized if it had continued the productive activities
$\checkmark$ Decline in sales in the automotive business, penalized in 2H 2021 by difficulties in the procurement of electronic components
$\checkmark$ Higher fees generated by the application developments in the actuator sector, favored by the prototyping activity on behalf of Rapitag GmbH
$\checkmark$ Net income tripled in 2021 mainly thanks to the financial income ( $€ 0.5$ million) for the partial waiver by the SAES Group of the interest accrued on the loans granted to Actuator Solutions

## SAES RIAL Vacuum - Income Statement

All figures in $M €$, unless otherwise stated

|  | 2021 | 2020 | Total difference | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 7.0 | 5.6 | 1.3 | 0.4 | 1.4 | 1.6 | 2.2 | 1.3 | 1.8 | 1.8 | 2.0 |
| Cost of goods sold | (5.8) | (4.2) | (1.6) | (0.5) | (1.0) | (1.2) | (1.6) | (1.2) | (1.6) | (1.3) | (1.8) |
| GROSS PROFIT | 1.2 | 1.5 | (0.3) | (0.1) | 0.4 | 0.5 | 0.7 | 0.1 | 0.3 | 0.5 | 0.3 |
| Gross Margin | 16.8\% | 25.7\% |  | -27.6\% | 29.2\% | 28.4\% | 30.2\% | 7.4\% | 15.7\% | 29.5\% | 12.5\% |
| Operating expenses | (0.7) | (0.6) | (0.1) | (0.1) | (0.1) | (0.1) | (0.2) | (0.2) | (0.2) | (0.1) | (0.2) |
| Other income (expenses), net | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | (0.0) | (0.0) |
| OPERATING INCOME | 0.6 | 0.9 | (0.3) | (0.2) | 0.3 | 0.3 | 0.5 | 0.0 | 0.1 | 0.4 | 0.1 |
| Operating Margin | 8.5\% | 16.4\% |  | -59.6\% | 20.5\% | 20.7\% | 23.0\% | 0.7\% | 7.6\% | 21.4\% | 2.7\% |
| Interest and other financial income (expenses), net | (0.0) | (0.0) | 0.0 | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0) | (0) |
| Foreign exchange gains (losses), net | (0.0) | 0.0 | (0.0) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.0) | (0) | 0 |
| INCOME BEFORE TAXES | 0.6 | 0.9 | (0.3) | (0.2) | 0.3 | 0.3 | 0.5 | 0.0 | 0.1 | 0 | 0 |
| Income Taxes | (0.1) | (0.3) | 0.1 | 0.1 | (0.1) | (0.1) | (0.2) | 0.0 | (0.0) | (0) | (0) |
| NET INCOME (LOSS) | 0.4 | 0.6 | (0.2) | (0.2) | 0.2 | 0.2 | 0.3 | 0.0 | 0.1 | 0 | 0 |

$\checkmark$ Net revenues up by $23.5 \%$ in 2021, being 2020 characterized by the delay of some large research projects, also due to the Covid-19 pandemic
$\checkmark$ Decline in gross margin due to a different product mix
$\checkmark$ The decrease in gross margin caused a decrease in gross profit, operating income and net income

## Flexterra - Income Statement

|  | 2021 | 2020 | Total difference | 1Q 2020 | 2Q 2020 | 3Q 2020 | 4Q 2020 | 1Q 2021 | 2Q 2021 | 3Q 2021 | 4Q 2021 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NET SALES | 0,0 | 0,1 | (0,0) | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Cost of goods sold | 0,0 | $(0,0)$ | 0,0 | $(0,0)$ | $(0,0)$ | 0,0 | 0,0 | 0,0 | $(0,0)$ | 0,0 | 0,0 |
| GROSS PROFIT | 0,0 | 0,0 | (0,0) | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Gross Margin | 260,0\% | 55,6\% |  | 43,3\% | 50,0\% | 100,0\% | n.s. | n.s. | 66,7\% | 100,0\% | $n . s$. |
| Operating expenses | $(3,9)$ | $(4,1)$ | 0,2 | $(1,1)$ | $(1,1)$ | $(1,0)$ | $(0,5)$ | $(1,0)$ | $(1,0)$ | $(1,0)$ | $(0,9)$ |
| Other income (expenses), net | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | $(0,0)$ | 0,0 | 0,0 | 0,0 | 0,0 |
| OPERATING INCOME | $(3,9)$ | $(4,1)$ | 0,2 | $(1,1)$ | $(1,1)$ | (1,0) | $(0,5)$ | $(1,0)$ | $(1,0)$ | $(1,0)$ | $(0,9)$ |
| Operating Margin | n.s. | n.s. |  | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| Interest and other financial income (expenses), net | $(0,3)$ | $(0,1)$ | $(0,2)$ | (0) | $(0,0)$ | $(0,0)$ | $(0,0)$ | $(0,1)$ | (0) | (0) | (0) |
| Foreign exchange gains (losses), net | 0,1 | 0,3 | $(0,2)$ | (0) | 0,1 | 0,1 | 0,1 | $(0,1)$ | 0 | 0 | 0 |
| InCOMEBEFORETAXES | $(4,1)$ | $(3,9)$ | $(0,2)$ | $(1,1)$ | $(1,0)$ | (0,9) | $(0,5)$ | $(1,1)$ | (1) | (1) | (1) |
| Income Taxes | $(0,0)$ | 0,0 | $(0,1)$ | 0 | 0,0 | 0,0 | 0,0 | 0,0 | (0) | 0 | 0 |
| NET INCOME(LOSS) | $(4,1)$ | $(3,9)$ | $(0,2)$ | $(1,1)$ | $(0,9)$ | $(0,9)$ | $(0,5)$ | $(1,1)$ | (1) | (1) | (1) |

$\checkmark$ Net loss equal to $-€ 4.1$ million in 2021, mainly due to costs for personnel employed in research activities and in general and administrative activities, consultancy fees, materials used in the development activity, costs related to the management of patents and amortization of intangible assets, including intellectual property
$\checkmark$ In 2H 2021 a $2^{\text {nd }}$ convertible loan (\$2M) granted by SAES to Flexterra
$\checkmark$ Cost saving started at the end of 2021, without any negative effect on Flexterra R\&D project

Total Income Statement of the Group - 2021
(achieved by incorporating the JVs with the proportional method instead of the equity method)

|  |  | Actuator Solutions |  | SAES RIAL Vacuum |  | Flexterra |  | 2021 <br> Total IS of the Group |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2021 | 50\% Actuator Solutions | Eliminations \& other adjs | 49\% SAES RIAL Vacuum S.r.I. | Eliminations \& other adjs | Flexterra (*) | Eliminations \& other adjs |  |
| NET SALES |  |  | (0.2) |  | (0.5) | 0.0 |  | 199.1 |
| Cost of sales | (108.9) | (4.0) | 0.2 | (2.0) | 0.5 | 0.0 |  | (114.1) |
| GROSS PROFIT | 81.3 | 1.6 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 83.5 |
| Gross Margin | 42.8\% | 26.3\% |  | 16.8\% |  | n.s. |  | 42.0\% |
| Total operating expenses | (57.8) | (1.2) |  | (0.3) |  | (1.8) | 0.1 | (61.2) |
| Other income (expenses), net | (0.8) | 0.1 |  | 0.1 |  | 0.0 |  | (0.7) |
| OPERATING INCOME | 22.6 | 0.5 | 0.0 | 0.3 | 0.0 | (1.8) | 0.1 | 21.7 |
| Operating Margin | 11.9\% | 7.8\% |  | 8.5\% |  | n.s. |  | 10.9\% |
| Interest and other financial income (expenses), net | (0.1) | 0.1 | (0.2) | (0.0) |  | (0.1) | 0.9 | 0.6 |
| Income (loss) from equity method evalueted companies | 0.2 |  |  |  | (0.2) |  |  | 0.0 |
| Write down of investments accounted for using the equity method Foreign exchange gains (losses), net | $\begin{array}{r} 0.0 \\ (0.2) \end{array}$ | (0.0) |  | (0.0) |  | 0.0 |  | 0.0 $(0.2)$ |
| INCOME BEFORE TAXES | 22.5 | 0.6 | (0.2) | 0.3 | (0.2) | (1.9) | 1.0 | 22.1 |
| Income Taxes | (9.4) | (0.0) |  | (0.1) |  | 0.0 |  | (9.5) |
| NET INCOME from continued operations | 13.1 | 0.6 | (0.2) | 0.2 | (0.2) | (1.9) | 1.0 | 12.6 |
| Net Margin | 6.9\% | 9.5\% |  | 5.9\% |  | n.s. |  | 6.3\% |
| Net income (loss) from discontinued operations | 0.0 |  |  |  |  |  |  | 0.0 |
| NET INCOME before minority interests | 13.1 | 0.6 | (0.2) | 0.2 | (0.2) | (1.9) | 1.0 | 12.6 |
| Net Margin | 6.9\% | 9.5\% |  | 5.9\% |  | n.s. |  | 6.3\% |
| Minority interests | 0.0 |  |  |  |  |  |  | 0.0 |
| GROUP NET INCOME | 13.1 | 0.6 | (0.2) | 0.2 | (0.2) | (1.9) | 1.0 | 12.6 |
| Net Margin | 6.9\% | 9.5\% |  | 5.9\% |  | n.s. |  | 6.3\% |

## Net Financial Position

|  | $\begin{gathered} \hline \text { Dec 31, } \\ 2021 \\ \hline \end{gathered}$ | $\begin{gathered} \hline \text { Sep 30, } \\ 2021 \end{gathered}$ | $\begin{gathered} \hline \text { Jun 30, } \\ 2021 \end{gathered}$ | $\begin{gathered} \hline \text { Mar 31, } \\ 2021 \end{gathered}$ | $\begin{gathered} \hline \text { Dec 31, } \\ 2020 \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Cash and cash equivalents | 29.5 | 36.0 | 24.4 | 28.7 | 30.7 |
| Current financial assets | 94.7 | 70.9 | 70.3 | 70.1 | 70.7 |
| Current financial liabilities | (66.5) | (75.7) | (50.2) | (42.6) | (40.7) |
| Current net financial position | 57.7 | 31.2 | 44.5 | 56.2 | 60.7 |
| Non current financial assets | 73.4 | 136.8 | 135.2 | 134.6 | 134.1 |
| Non current financial liabilities | (56.3) | (97.7) | (97.3) | (98.4) | (99.1) |
| Non current financial position | 17.1 | 39.0 | 37.9 | 36.2 | 35.1 |
| NET FINANCIAL POSITION | 74.8 | 70.2 | 82.4 | 92.4 | 95.7 |

$\checkmark$ To reduce the Group's interest burden, at the end of December 2021:

- Advance repayment of the loan with Mediobanca
- Divestment of Cardif Lux Vie Multiramo Policy - Line I
- New Lombard loan with JP Morgan (€52 million)
Operating activity Investing activity Financing activity Exchange rate effect
$\checkmark$ Decrease mainly attributable to Cinel acquisition ( $-€ 16$ million), to net investments in tangible and intangible fixed assets ( $-€ 16.6$ million) and to the dividends (- $€ 7.4$ million)
$\checkmark$ Operating cash flows equal to $+€ 19.2$ million, penalized by the increase in WC (mainly higher ARs and Inventory)
$\checkmark$ Within the investing activity, positive cash flows ( $+€ 3.5$ million) from securities and negative cash flows ( $-€ 0.2$ million) from the investment in EUREKA!
$\checkmark$ Within the financing activity, financial payables for leases ( $-€ 3.1$ million) and for net interests accrued on loans ( $-€ 1.5$ million)
$\checkmark$ Positive exchange rate effect ( $+€ 2.8$ million)


## Net Financial Position - QTD trend


$\checkmark$ Increase mainly attributable to operating cash flows (+€10.6 million), partially offset by net investments in fixed assets ( $-€ 4.2$ million) and by the write-down of the principal amount of the convertible note granted to Flexterra, Inc. in 2 H 2021 (-€1.7 million)

Cash Flows - YTD

|  | 2021 | 2020 |
| :---: | :---: | :---: |
| Net income (loss) from continued operations | 13.1 | 4.8 |
| Net income (loss) from discontinued operations | 0.0 | 0.0 |
| Current income taxes | 8.0 | 5.2 |
| Change in deferred income taxes | 0.9 | (1.0) |
| Depreciation, amortization and write down of non current assets | 13.2 | 10.9 |
| Interest and other financial (income) expenses, net | (0.0) | 6.6 |
| Other non-monetary costs (revenues) | 1.8 | 2.1 |
|  | 37.0 | 28.5 |
| Change in operating assets and liabilities | (9.6) | (8.4) |
| Payments of termination indemnities and similar obligations | (0.7) | (0.4) |
| Financial income received, net of payment of interests | (0.2) | (0.4) |
| Taxes paid | (7.3) | (6.5) |
| Net cash flows from operating activities | 19.2 | 12.8 |
| Purchase of tangible and intangible assets, net of proceeds from sales | (16.6) | (13.2) |
| Purchase of securities, net of disinvestments | 39.9 | (1.2) |
| Income from securities, net of management fees | 1.9 | 2.1 |
| Purchase of other investments | (0.2) | (1.4) |
| Acquisition of controlled subsidiaries, net of cash acquired | (15.8) | 0.0 |
| Net cash flows from investing activities | 9.2 | (13.6) |
| Proceeds from financial liabilities, net of repayments | (18.3) | 0.2 |
| Financial receivables repaid (granted) from related parties | (1.7) | (2.6) |
| Interests receipts on financial receivables from related parties | 0.0 | 0.0 |
| Dividends payment | (7.4) | (9.2) |
| Interests and other expenses paid on loans | (1.5) | (1.4) |
| Repayment of financial liabilities for leased assets (interests included) | (2.5) | (2.2) |
| Financial receivables repaid (granted) from third parties | (1.4) | 0.0 |
| Other financial liabilities/assets | (0.0) | (0.0) |
| Net cash flows from financing activities | (32.8) | (15.3) |
| Effect of exchange rate differences | 3.0 | (1.7) |
| TOTAL CASH FLOWS | (1.4) | (17.8) |

## Sees

## February 2022 - Sales

| Business | Feb-22 | Feb-21 | Total difference | Organic change | Exchange rate effect | Perimeter effect |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Getters \& Dispensers | 8.2 | 7.5 | 9.6\% | 5.2\% | 4.4\% | 0.0\% |
| Sintered Materials | 1.6 | 1.1 | 35.6\% | 26.6\% | 9.0\% | 0.0\% |
| SMA Materials | 2.3 | 1.9 | 21.7\% | 19.0\% | 2.7\% | 0.0\% |
| Metallurgy Division | 12.1 | 10.6 | 14.6\% | 10.0\% | 4.6\% | 0.0\% |
| High Vacuum Solutions | 4.6 | 2.2 | 110.9\% | 53.1\% | 3.2\% | 54.6\% |
| SAES High Vacuum | 4.6 | 2.2 | 110.9\% | 53.1\% | 3.2\% | 54.6\% |
| Medical Nitinol | 17.2 | 11.1 | 54.4\% | 44.2\% | 10.2\% | 0.0\% |
| SAES Medical Nitinol | 17.2 | 11.1 | 54.4\% | 44.2\% | 10.2\% | 0.0\% |
| Chemicals | 2.3 | 1.6 | 45.7\% | 45.7\% | 0.0\% | 0.0\% |
| SAES Chemicals | 2.3 | 1.6 | 45.7\% | 45.7\% | 0.0\% | 0.0\% |
| Packaging Solutions | 2.0 | 1.1 | 83.0\% | 83.0\% | 0.0\% | 0.0\% |
| SAES Packaging | 2.0 | 1.1 | 83.0\% | 83.0\% | 0.0\% | 0.0\% |
| Total net sales | 38.2 | 26.5 | 43.9\% | 33.1\% | 6.3\% | 4.5\% |

$\checkmark$ Organic growth mainly driven by the Medical Nitinol Division (in the first two months of 2021 suffering from the prolonged effects of the pandemic)
$\checkmark \quad$ In the Packaging Division consolidation of the signs of recovery already shown in the last months of 2021

## Business Outlook

$>$ In the next few months further growth is expected in the medical sector and in the vacuum systems business, as well as the consolidation of the signs of recovery, which already appeared at the end of 2021, in the sales activities of shape memory alloys for mobile phone applications and in the packaging business
> Marginal SAES direct exposure in Russia, Ukraine and Belarus. SAES turnover concentrated in Russia is immaterial and no suppliers are from this country. However, the unpredictable dynamics of the geopolitical, military and economic developments of the crisis, combined with the complex interdependencies between the world's economies and supply chains, do not allow to provide firm estimates of the crisis' impact

## Disclaimer and Attestation

This presentation contains forward-looking statements which are based upon current expectations and involve a number of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forwardlooking statements made by the Company. These factors include the Company's ability to introduce new products at planned costs and on planned schedules, the Company's ability to maintain key client relationships and the environments of the various economies in the countries the Company conducts business. The Company cautions that the foregoing list of important factors is not exclusive. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

The Officer Responsible for the preparation of corporate financial reports of SAES Getters S.p.A. certifies that, in accordance with the second subsection of article 154-bis, part IV, title III, second paragraph, section V-bis, of Legislative Decree February 24, 1998, no. 58, the financial information included in the present document corresponds to book of account and book-keeping entries.

The Officer Responsible for the preparation of corporate financial reports
Giulio Canale

[^3]
## Thank you for your attention


[^0]:    $\checkmark$ Increased sales of advanced materials in the consumer electronics business
    $\checkmark$ Higher sales of dispensable dryers for passive matrix OLED displays and for saturimeter displays
    $\checkmark$ Higher sales active sealants for other electronic applications

[^1]:    $\checkmark$ Increase due to higher consolidated revenues
    $\checkmark$ Increase in revenues of SAES RIAL Vacuum offset by the lower revenues of Actuator Solutions
    $\checkmark$ Decrease in Actuator Solutions revenues only figurative: without considering the outsourcing of production, 2021 sales substantially in line with 2020

[^2]:    $\checkmark$ Significant improvement in all indicators starting from the last part of the year

[^3]:    SAES ${ }^{\circ}$ is a registered trademark of SAES Getters S.p.A.

